# Arog Pharmaceuticals

Source: https://onco.cc/companies/arog-pharmaceuticals/  
OnCo record `arog-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Arog is a private Dallas biotech developing crenolanib, a FLT3 and PDGFR kinase inhibitor, through phase 3 trials in FLT3-mutant acute myeloid leukaemia and gastrointestinal stromal tumours.

## Summary

Arog Pharmaceuticals, based in Dallas, Texas, licensed crenolanib from Pfizer and has taken it into phase 3 trials in newly diagnosed and relapsed FLT3-mutated acute myeloid leukaemia and in PDGFRA D842V-mutant gastrointestinal stromal tumours, all registered on ClinicalTrials.gov under Arog as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Arog Pharmaceuticals, Inc.; AROG
- Tags: ctgov-sponsor
- HQ: Dallas, TX
- Type: biotech
- Website: https://www.arogpharma.com

## Sources

- Official website: https://www.arogpharma.com
- ClinicalTrials.gov: trials led by Arog Pharmaceuticals, Inc.: https://clinicaltrials.gov/search?lead=Arog%20Pharmaceuticals%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q30286808

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/)
- targets: [FLT3](https://onco.cc/targets/flt3/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/arog-pharmaceuticals.json